CU23496A1 - Composición vacunal contra el virus de la hepatitis c - Google Patents

Composición vacunal contra el virus de la hepatitis c

Info

Publication number
CU23496A1
CU23496A1 CU20040189A CU20040189A CU23496A1 CU 23496 A1 CU23496 A1 CU 23496A1 CU 20040189 A CU20040189 A CU 20040189A CU 20040189 A CU20040189 A CU 20040189A CU 23496 A1 CU23496 A1 CU 23496A1
Authority
CU
Cuba
Prior art keywords
hepatitis
virus
vaccine composition
composition against
structural
Prior art date
Application number
CU20040189A
Other languages
English (en)
Inventor
Lasa Alexis Musacchio
Tsibulova Maria Guirola
Garcia Gretel Sardinas
Donato Gillian Martinez
Ponce De Leon Liz Alvarez-Lajonchere
Rivero Nelson Acosta
Carrera Santiago Duenas
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20040189A priority Critical patent/CU23496A1/es
Priority to ARP050103513 priority patent/AR052639A1/es
Priority to RU2007112117A priority patent/RU2351363C2/ru
Priority to HK07114321.4A priority patent/HK1109069B/xx
Priority to AU2005279590A priority patent/AU2005279590B2/en
Priority to KR1020077006792A priority patent/KR101245154B1/ko
Priority to CN2005800362181A priority patent/CN101043902B/zh
Priority to JP2007528569A priority patent/JP4917539B2/ja
Priority to US11/661,217 priority patent/US20080138360A1/en
Priority to MX2007002659A priority patent/MX2007002659A/es
Priority to EP20050779477 priority patent/EP1785143B1/en
Priority to BRPI0514884-7A priority patent/BRPI0514884A/pt
Priority to CA 2577918 priority patent/CA2577918C/en
Priority to PCT/CU2005/000005 priority patent/WO2006024240A2/es
Priority to ZA200701674A priority patent/ZA200701674B/xx
Publication of CU23496A1 publication Critical patent/CU23496A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composición vacunal para el tratamiento terapéutico y profiláctico de la hepatitis C, la cual contiene como componentes la mezcla de los antígenos estructurales del virus de la Hepatitis C, en este caso la proteína de la cápsida, la proteína estructural E1 y la proteína estructural E2, en proporciones adecuadas y que ejercen un efecto potenciador en el desarrollo de la respuesta inmune contra este virus. Vacunas combinadas contra entidades patógenas incluyendo esta composición vacunal son también descritas.
CU20040189A 2004-09-03 2004-09-03 Composición vacunal contra el virus de la hepatitis c CU23496A1 (es)

Priority Applications (15)

Application Number Priority Date Filing Date Title
CU20040189A CU23496A1 (es) 2004-09-03 2004-09-03 Composición vacunal contra el virus de la hepatitis c
ARP050103513 AR052639A1 (es) 2004-09-03 2005-08-22 Composicion vacunal contra el virus de la hepatitis c.
RU2007112117A RU2351363C2 (ru) 2004-09-03 2005-08-29 Вакцинная композиция против вируса гепатита с
HK07114321.4A HK1109069B (en) 2004-09-03 2005-08-29 Vaccine composition against hepatitis c virus
AU2005279590A AU2005279590B2 (en) 2004-09-03 2005-08-29 Vaccine composition against hepatitis C virus
KR1020077006792A KR101245154B1 (ko) 2004-09-03 2005-08-29 간염 ｃ 바이러스에 대한 백신 조성물
CN2005800362181A CN101043902B (zh) 2004-09-03 2005-08-29 针对丙型肝炎病毒的疫苗组合物
JP2007528569A JP4917539B2 (ja) 2004-09-03 2005-08-29 Ｃ型肝炎ウイルスに対するワクチン組成物
US11/661,217 US20080138360A1 (en) 2004-09-03 2005-08-29 Vaccine Composition Against Hepatitis C Virus
MX2007002659A MX2007002659A (es) 2004-09-03 2005-08-29 Composicion vacunal contra el virus de la hepatitis c.
EP20050779477 EP1785143B1 (en) 2004-09-03 2005-08-29 Vaccine composition against hepatitis c virus
BRPI0514884-7A BRPI0514884A (pt) 2004-09-03 2005-08-29 composição vacinal para gerar resposta imune celular e humoral protetora contra a infecção pelo vìrus de hepatite c
CA 2577918 CA2577918C (en) 2004-09-03 2005-08-29 Vaccine composition against hepatitis c virus
PCT/CU2005/000005 WO2006024240A2 (es) 2004-09-03 2005-08-29 Composición vacunal contra el virus de la hepatitis c.
ZA200701674A ZA200701674B (en) 2004-09-03 2007-02-26 Vaccine composition against Hepatitis C virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20040189A CU23496A1 (es) 2004-09-03 2004-09-03 Composición vacunal contra el virus de la hepatitis c

Publications (1)

Publication Number Publication Date
CU23496A1 true CU23496A1 (es) 2010-02-23

Family

ID=40262832

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20040189A CU23496A1 (es) 2004-09-03 2004-09-03 Composición vacunal contra el virus de la hepatitis c

Country Status (14)

Country Link
US (1) US20080138360A1 (es)
EP (1) EP1785143B1 (es)
JP (1) JP4917539B2 (es)
KR (1) KR101245154B1 (es)
CN (1) CN101043902B (es)
AR (1) AR052639A1 (es)
AU (1) AU2005279590B2 (es)
BR (1) BRPI0514884A (es)
CA (1) CA2577918C (es)
CU (1) CU23496A1 (es)
MX (1) MX2007002659A (es)
RU (1) RU2351363C2 (es)
WO (1) WO2006024240A2 (es)
ZA (1) ZA200701674B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE032422T2 (en) 2006-09-29 2017-09-28 Takeda Vaccines Inc Norovirus vaccine preparations
SG10201601660YA (en) 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
AU2009279456B2 (en) * 2008-08-08 2015-02-05 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
EA029470B1 (ru) 2011-07-11 2018-03-30 Такеда Вэксинс, Инк. Способ стимулирования формирования защитного иммунитета против норовируса
RU2510998C2 (ru) * 2012-08-01 2014-04-10 Николай Николаевич Грановский ВАКЦИНА НА ОСНОВЕ ВИРУСОПОДОБНЫХ ЧАСТИЦ, СОДЕРЖАЩИХ ВСЕ СТРУКТУРНЫЕ АНТИГЕНЫ ВИРУСА ГЕПАТИТА С, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ В ДРОЖЖАХ Hansenula polymorpha
CU24112B1 (es) * 2012-11-05 2015-08-27 Ct De Ingeniería Genética Y Biotecnología Antígenos vacunales quiméricos contra el virus de la hepatitis c

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070790B1 (en) * 1993-06-29 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
NZ296304A (en) * 1994-10-05 1999-06-29 Apollon Hepatitis c vaccine components
AU738585B2 (en) * 1996-11-08 2001-09-20 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Synthesis and purification of hepatitis C virus-like particles
WO2001037869A1 (en) * 1999-11-19 2001-05-31 Csl Limited Vaccine compositions
AU2002225895A1 (en) * 2000-11-07 2002-05-21 Anadys Pharmaceuticals, Inc. Hepatitis c virus constructs characterized by high efficiency replication
US7101561B2 (en) * 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US20030021805A1 (en) * 2001-05-29 2003-01-30 Barber Glen N. Generation of HCV-like particles and chimeric HCV virus
CU23244A1 (es) * 2001-07-16 2007-10-17 Ct Ingenieria Genetica Biotech Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
DE10143490C2 (de) * 2001-09-05 2003-12-11 Gsf Forschungszentrum Umwelt Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen

Also Published As

Publication number Publication date
KR101245154B1 (ko) 2013-03-19
BRPI0514884A (pt) 2008-06-24
MX2007002659A (es) 2007-05-16
AU2005279590B2 (en) 2010-12-16
WO2006024240A3 (es) 2006-06-01
EP1785143A2 (en) 2007-05-16
CN101043902A (zh) 2007-09-26
US20080138360A1 (en) 2008-06-12
EP1785143B1 (en) 2015-03-04
CA2577918C (en) 2013-05-28
RU2351363C2 (ru) 2009-04-10
AU2005279590A1 (en) 2006-03-09
JP2008511556A (ja) 2008-04-17
JP4917539B2 (ja) 2012-04-18
CN101043902B (zh) 2012-04-18
KR20070057861A (ko) 2007-06-07
HK1109069A1 (en) 2008-05-30
CA2577918A1 (en) 2006-03-09
ZA200701674B (en) 2008-08-27
WO2006024240A2 (es) 2006-03-09
RU2007112117A (ru) 2008-10-10
AR052639A1 (es) 2007-03-28

Similar Documents

Publication Publication Date Title
BR112018009009A2 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EA201391515A1 (ru) Инактивированная вакцина вируса денге
EA201071087A1 (ru) Моноклональные антитела, способные взаимодействовать с множеством подтипов вируса гриппа а
ATE426412T1 (de) Adjuvante influenza-vakzine
EP1948229A4 (en) COMBINATION VACCINE WITH A STEAMED BOVINE VIRUS DIARRHEA VIRUS
WO2014205199A3 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
AR061894A1 (es) Vacunas para malaria
CO6440541A2 (es) Virus de diarrea viral bovina con una proteina erns modificada
PE20151588A1 (es) Vacuna contra el virus del dengue
MX388128B (es) Vacuna combinada para cerdos.
CY1110744T1 (el) Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c
AR101814A1 (es) Partícula de tipo virus flavivirus
CL2016000300A1 (es) Métodos terapéuticos
MX391930B (es) Vacuna contra la fiebre aftosa.
EA201690115A1 (ru) Комбинированные иммуногенные композиции
CO2020004801A2 (es) Uso de suplementos de aminoácidos para mejorar la síntesis de proteínas musculares
PH12018502436A1 (en) Multivalent vaccines major swine viral diseases
CU23496A1 (es) Composición vacunal contra el virus de la hepatitis c
UY35418A (es) Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
EA200901064A1 (ru) Лекарственное средство для лечения гриппа у птиц
MX2011006516A (es) Terapia de combinacion de virus de hepatitis c.
ATE479440T1 (de) Virusstämme und zusammensetzungen des prrs- syndroms (porcine reproductive und respiratory syndrome) von schweinen

Legal Events

Date Code Title Description
FG Grant of patent
FD Lapse (for not paying fees)